Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 128

Results For "Post"

1357 News Found

Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22
Healthcare | August 08, 2021

Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22

Board approves fundraise of Rs 1500 crore

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US

Abbott India net profit rises to 8.5 per cent in Q1FY22
News | August 08, 2021

Abbott India net profit rises to 8.5 per cent in Q1FY22

PAT rises to Rs 195.76 crore

India’s gets its first bio-bank for heart failure research
Drug Approval | August 06, 2021

India’s gets its first bio-bank for heart failure research

Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology

Apollo Hospitals successfully implants MitraClip
Healthcare | August 05, 2021

Apollo Hospitals successfully implants MitraClip

MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery

Covaxin receives approval from Hungary
Biotech | August 05, 2021

Covaxin receives approval from Hungary

More countries recognise Covaxin

IPCA Labs reports Q1FY22 net at Rs 306.66 Cr
News | August 05, 2021

IPCA Labs reports Q1FY22 net at Rs 306.66 Cr

Total income grew in the quarter

Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22
News | August 04, 2021

Solara Active Pharma Science clocks net profit of Rs 50.13 crore in Q1FY22

Aditya Puri former MD of HDFC bank joins Solara board as chairman

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
Healthcare | August 03, 2021

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22

Nureca Ltd has reported financial results for the period ended June 30, 2021.

Healthium Medtech acquires SGK Lab’s AbGel gelatin business
Healthcare | August 03, 2021

Healthium Medtech acquires SGK Lab’s AbGel gelatin business

Complementary business models are the reason for the acquisition

Latest Stories

Glycomine completes enrollment in Phase 2b trial for rare genetic disorder

Zeto gains FDA nod for new outpatient EEG system promising faster brain health testing

Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging